Nexstim logo

Notice of Nexstim Plc’s Half-Yearly Report H1 2016

10 August 2016

Notice of Nexstim Plc’s Half-Yearly Report H1 2016

Company announcement, Helsinki, 10 August 2016, at 9:00 am

Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company with a pioneering navigated non-invasive brain stimulation system, will publish its half-yearly report for the six months ended 30 June 2016 on Wednesday 17 August 2016 at approximately 9.00 am Finnish time.

A conference call for media, investors and analysts will take place at 3.00 pm Finnish time on Wednesday 17 August 2016. Martin Jamieson, Chairman and CEO, and Mikko Karvinen, CFO, will present the financial and operational results followed by a Q&A session.

The dial-in numbers for the conference call are:

Finland:    +358 9 23195187
Sweden:  +46 850336434
UK:           +44 1452 555 566
US:           +1 631 5107 498

The call ID number is: 58978731

Financial statements release for the year ending 31 December, 2016 will be published on or about 28 February 2017.

NEXSTIM PLC

Martin Jamieson, Chairman & CEO

Further information is available on the website www.nexstim.com or by contacting:

Nexstim                                                                                                          +447715163942

Martin Jamieson, Chairman & CEO                                           martin.jamieson@nexstim.com                                                                                                                          

UB Securities Oy (Certified Adviser)                                                          +358 (0)9 2538 0246

Consilium Strategic Communications                                                       +44 (0)20 3709 5700

Mary-Jane Elliott / Ivar Milligan / Laura Thornton                     nexstim@consilium-comms.com

About Nexstim Plc

Nexstim is a medical technology company which has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) system for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the company has developed a system called Navigated Brain Therapy (NBT®) which is CE-marked for chronic neuropathic pain, major depression and stroke therapy. Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com

 

Back to Press Releases

Sorry, there are no fact sheets available. Please check back soon.

Follow us

linkedin

Twitter
YouTube